Quantcast
Home > Quotes > GNMX

Aevi Genomic Medicine, Inc. Common Stock (GNMX) Quote & Summary Data

GNMX 
$0.203
*  
0.0023
1.12%
Get GNMX Alerts
*Delayed - data as of May 24, 2019  -  Find a broker to begin trading GNMX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 0.205 / $ 0.186
Share Volume
313,827
50 Day Avg. Daily Volume
1,831,923
Previous Close
$ 0.2053
52 Week High / Low
$ 1.72 / $ 0.1718
Market Cap
13,147,677
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
313,827
50 Day Avg. Daily Volume:
1,831,923

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.54

Trading Range

The current last sale of $0.203 is 18.16% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.205 $ 1.72
 Low: $ 0.186 $ 0.1718

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. We look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. We have partnered with the Center for Applied Genomics, or CAG, at The Children's Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug development.  ... More ...  



Risk Grade

Where does GNMX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.2002
Open Date:
May 24, 2019
Close Price:
$ 0.2024
Close Date:
May 24, 2019


Consensus Recommendation

Analyst Info